Dyne Therapeutics director receives 35,152 stock options

Dyne Therapeutics director Dirk Kersten received a new stock option grant as part of his compensation.

Rhea-AI Filing Summary

Dyne Therapeutics director Dirk Kersten received a new stock option grant as part of his compensation. On June 5, 2026, he was awarded options covering 35,152 shares of common stock at an exercise price of $17.04 per share.

The option vests in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, as long as Kersten continues to serve the company. After this grant, he holds 35,152 stock options directly, and there are no additional derivative holdings shown in this filing.

Insights

Equity compensation analyst

Routine director stock option grant with time-based vesting.

Dyne Therapeutics granted director Dirk Kersten stock options for 35,152 shares of common stock at an exercise price of $17.04 per share. The grant is recorded with a transaction code A, indicating a grant or award rather than a market purchase.

The options vest in full on the earlier of June 5, 2027 or the 2027 Annual Meeting of Stockholders, subject to continued service. This time-based vesting is typical for director compensation and does not involve any open-market buying or selling activity.

Because the transaction is a standard equity award with no sales and represents compensation rather than a discretionary trade, its informational value for short-term trading sentiment is limited. Future company filings may detail additional grants or any eventual exercises or dispositions of these options.

Insider Trade Summary

Grant/Award: 35,152 shares

Grant/Award 1 txn

Insider Kersten Dirk

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	35,152	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 35,152 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

Key Figures

Option grant size: 35,152 shares Exercise price: $17.04 per share Post-grant option holdings: 35,152 options +2 more

5 metrics

Option grant size 35,152 shares Stock option grant on June 5, 2026

Exercise price $17.04 per share Conversion or exercise price of options

Post-grant option holdings 35,152 options Total derivative shares following transaction

Option expiration June 4, 2036 Expiration date of stock options

Vesting date trigger Earlier of June 5, 2027 or 2027 annual meeting Full vesting condition subject to continued service

Key Terms

Stock option (right to buy), Grant, award, or other acquisition, vest in full, Annual Meeting of Stockholders

4 terms

Stock option (right to buy) financial

"security_title: "Stock option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

vest in full financial

"The shares underlying the option are scheduled to vest in full on the earlier of"

Annual Meeting of Stockholders financial

"the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Dyne Therapeutics (DYN) director Dirk Kersten report in this Form 4?

Dirk Kersten reported receiving a stock option grant for 35,152 shares of Dyne Therapeutics common stock. The options carry an exercise price of $17.04 per share and represent a compensation award, not an open-market share purchase or sale.

How many Dyne Therapeutics (DYN) shares are covered by Dirk Kersten’s new stock options?

The new stock option grant covers 35,152 shares of Dyne Therapeutics common stock. These options give Kersten the right to buy that number of shares at a fixed exercise price, subject to the vesting conditions described in the filing’s footnote.

What is the exercise price of Dirk Kersten’s Dyne Therapeutics (DYN) stock options?

The exercise price of the stock options granted to Dirk Kersten is $17.04 per share. This means he can purchase Dyne Therapeutics common stock at $17.04 per share once the options vest and remain exercisable until their expiration date.

When do Dirk Kersten’s Dyne Therapeutics (DYN) stock options vest?

The options are scheduled to vest in full on the earlier of June 5, 2027 or the 2027 Annual Meeting of Stockholders. Vesting is subject to Kersten’s continued service with Dyne Therapeutics through that vesting date, according to the filing footnote.

What is the expiration date of Dirk Kersten’s Dyne Therapeutics (DYN) stock options?

The stock options granted to Dirk Kersten expire on June 4, 2036. After that expiration date, any unexercised options would lapse and could no longer be used to purchase Dyne Therapeutics common stock under this grant.

Does the Form 4 for Dyne Therapeutics (DYN) show any stock sales by Dirk Kersten?

The Form 4 does not report any stock sales by Dirk Kersten. It records a single derivative transaction coded as a grant or award of stock options, with no open-market buy or sell transactions included in the summarized data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 05:12 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kersten Dirk

(Last) (First) (Middle)

C/O DYNE THERAPEUTICS, INC.

1560 TRAPELO ROAD

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dyne Therapeutics, Inc. [ DYN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$17.04	06/05/2026		A		35,152		(1)	06/04/2036	Common Stock	35,152	$0.00	35,152	D

Explanation of Responses:

1. This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

	/s/ Ron Caponigro, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)